论文部分内容阅读
目的以153Sm标记的抗C-erbB-2单克隆抗体对荷人乳腺癌移植瘤裸鼠进行肿瘤预定位显像的研究。为乳腺癌早期诊断提供一种新方法,并为其临床应用提供实验依据。方法实验I组每只裸鼠采用三步预定位法从尾静脉注射7.4 MBq/0.1 ml的153Sm-DTPA-C-erbB-2 McAb实验II组与II组分别直接从尾静脉注射7.4 MBq/0.1 ml的135 Sm-C-erbB-2及135Sm-IgG并于于注射后2、4、8、24h行全身SPECT显像。于4、82、4 h分批处死裸鼠并测定分别在肿瘤、血液、心脏、肺等重要脏器单位重量的放射性比值(%ID/g)。结果在运用预定位技术加药的实验I组在给药后2小时开始有抗体在肿瘤组织浓聚,在8小时时达到最高,与实验II组直接给予抗体比较,血液本底低,两组比较差异有显著性(P<0.05)。结论应用预定位技术的实验组,瘤/血液比值高,血液本底低,周围正常组织吸收剂量低,显像效果好。
OBJECTIVE: To study the imaging of tumor pre-location with 153Sm labeled anti-C-erbB-2 monoclonal antibody in nude mice bearing human breast cancer xenografts. Provide a new method for the early diagnosis of breast cancer and provide experimental evidence for its clinical application. Methods In group I, 7.4 MBq / 0.1 ml of 153Sm-DTPA-C-erbB-2 McAb was injected into the caudal vein of each nude mouse by a three-step pretargeting method. Groups II and II were injected with 7.4 MBq / 0.1 ml of 135 Sm-C-erbB-2 and 135Sm-IgG. SPECT imaging was performed at 2, 4, 8 and 24 hours after injection. Nude mice were sacrificed in batches at 4,82,4 h, and the radioactivity ratio (% ID / g) of each unit weight in important organs such as tumor, blood, heart and lung was measured. Results In the experimental group I with pretargeting technique, the antibody concentration in tumor tissue started at 2 hours after administration and reached the highest level at 8 hours. Compared with the direct administration of antibody in experimental group II, the blood background was low. Both groups The difference was significant (P <0.05). Conclusion The experimental group with pre-positioning technique has high tumor / blood ratio, low blood background, low absorbed dose in normal tissue around, and good imaging effect.